Lower Rates of Symptom Rebound Seen After H. Pylori Eradication in GERD

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, March 6, 2025 -- For patients with gastroesophageal reflux disease (GERD), those with Helicobacter pylori infection have significantly lower rates of symptom rebound and rebound severity after bacterial eradication and proton-pump inhibitor (PPI) therapy, according to a study published online Feb. 26 in Helicobacter.

Kai-Yu Hu, from the National Taiwan University Hospital in Taipei, and colleagues recruited patients with typical reflux symptoms and reflux esophagitis on esophagogastroduodenoscopy to examine the effect of H. pylori eradication on the rebound of reflux-related symptoms. Patients who were positive for H. pylori were randomly assigned to receive bacterial eradication with triple therapy for two weeks before or after four weeks of PPI therapy.

Two hundred forty-eight patients were enrolled; 43.1 percent tested positive for H. pylori. The researchers found significant symptom improvement over the entire treatment for all patients with and without concurrent H. pylori infection. Compared with those without, patients with H. pylori infection had significantly lower rates of symptom rebound (19.8 versus 34.2 percent) and rebound severity (1.8 ± 0.7 versus 2.8 ± 1.6) four weeks after eradication and PPI treatment. No significant difference was seen between the early and late eradication groups in terms of incidence rates of symptom rebound and successful eradication rates.

"The present study demonstrates that GERD patients without H. pylori infection were more vulnerable to experiencing rebound of reflux-related symptoms after PPI discontinuation," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-07 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords